<DOC>
	<DOCNO>NCT02392221</DOCNO>
	<brief_summary>Crohn 's disease ( CD ) ulcerative colitis ( UC ) chronic Inflammatory Bowel Disease ( IBD ) may affect segment digestive tract . These disease multifactorial origin environmental genetic factor predominant.The EPIMAD registry , world 's large epidemiological register IBD , identify incident case four department North West France show 1988 2007 , increase annual incidence MC 71 % ( 6.5 / 105 ( 1988-1990 ) 11.1 / 105 ( 2006-2007 ) p &lt; 0.0001 ) age group 10-19 year . At time , annual incidence UC decrease 4.3 / 3.5 105 inhabitant / 105 inhabitant ( 20 % ) , phenotypic presentation remain stable . The increase incidence CD contribute increase weight health system , particularly pediatric CD frequently associate aggressive phenotype cause specific complication malnutrition , pubertal delay thrive . These complication important impact quality life long-term risk functional disability . They may associate increased mortality . Immunosuppressants ( azathioprine , methotrexate ) use pediatric form 90 anti-TNF antibody ( infliximab adalimumab ) , 2000s . These new therapeutic class profoundly change management pediatric IBD . Although little data impact new treatment , early introduction immunosuppressive anti-TNFs seem influence natural history IBD diagnose pediatric age . Anti-TNFs appear associate frequent deep remission . With advent new treatment , new therapeutic target endoscopic mucosal heal recently deep remission combine clinical remission , biological endoscopic , appear . However data general population assess impact new treatment new therapeutic strategy pediatric population . Potential risk associate increase use early use biological treatment particular population remain determine general population . The main hypothesis study change therapeutic strategy IBD diagnose 17 yeras old could influence cumulative incidence surgical resection complication specific population failure thrive delay puberty , insertion socio-professional , extension disease , hospitalization rate , rate cancer .</brief_summary>
	<brief_title>Impact Therapeutic Strategies Pediatric Inflammatory Bowel Disease : Population Based Study ( 1988-2008 ) .</brief_title>
	<detailed_description>Crohn 's disease ( CD ) ulcerative colitis ( UC ) chronic Inflammatory Bowel Disease ( IBD ) may affect segment digestive tract . These disease multifactorial origin environmental genetic factor predominant.The EPIMAD registry , world 's large epidemiological register IBD , identify incident case four department North West France show 1988 2007 , increase annual incidence MC 71 % ( 6.5 / 105 ( 1988-1990 ) 11.1 / 105 ( 2006-2007 ) p &lt; 0.0001 ) age group 10-19 year . At time , annual incidence UC decrease 4.3 / 3.5 105 inhabitant / 105 inhabitant ( 20 % ) , phenotypic presentation remain stable . The increase incidence CD contribute increase weight health system , particularly pediatric CD frequently associate aggressive phenotype cause specific complication malnutrition , pubertal delay thrive . These complication important impact quality life long-term risk functional disability . They may associate increased mortality . Immunosuppressants ( azathioprine , methotrexate ) use pediatric form 90 anti-TNF antibody ( infliximab adalimumab ) , 2000s . These new therapeutic class profoundly change management pediatric IBD . Although little data impact new treatment , early introduction immunosuppressive anti-TNFs seem influence natural history IBD diagnose pediatric age . Anti-TNFs appear associate frequent deep remission . With advent new treatment , new therapeutic target endoscopic mucosal heal recently deep remission combine clinical remission , biological endoscopic , appear . However data general population assess impact new treatment new therapeutic strategy pediatric population . Potential risk associate increase use early use biological treatment particular population remain determine general population . The main hypothesis study change therapeutic strategy IBD diagnose 17 yeras old could influence cumulative incidence surgical resection complication specific population failure thrive delay puberty , insertion socio-professional , extension disease , hospitalization rate , rate cancer .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Patients pediatric cohort EPIMAD registry diagnosis CD UC probable 1988 2008 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's disease ( CD )</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>